LIBERTY HEALTH SCIENCES update...

originally published Tuesday, November 28, 2017

Printable Version

All Marijuana stocks

Liberty Health Sciences has more than doubled since we went for it in October and again in November, which is not bad going for a cannabis stock with 284 million shares in issue. The rise this month has been relentless, but it has been accelerating, and in recent days volume has become heavy, which means that there is an increasing risk that it will blow out soon with a sharp reversal, which could be made worse by the fact that there have been virtually no down days for weeks. Sure it could go higher, could even spike dramatically, but we’ll let others find out if that happens. TAKE PROFITS IMMEDIATELY.


Liberty was the subject of an Email alert sent out before the open this morning (at 9.26 am EST) which read as follows…

“Liberty Health Sciences has more than doubled since we went for it in October and again in November, which is not bad going for a cannabis stock with 284 million shares in issue. The rise this month has been relentless, but it has been accelerating, and in recent days volume has become heavy, which means that there is an increasing risk that it will blow out soon with a sharp reversal, which could be made worse by the fact that there have been virtually no down days for weeks. Sure it could go higher, could even spike dramatically, but we’ll let others find out if that happens. TAKE PROFITS IMMEDIATELY.

An article with latest chart is in preparation, but there is no time to get it up in good order before the open, hence this Email alert.”


Liberty Health Sciences, LHS on CSX, LHSIF on OTC, closed at C$2.39, $1.87 on 27th November 17.


Posted at 9.45 am EST on 28th November 17.

The above represents the opinion and analysis of Mr Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stockmarket analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.